OPEN END TURBO OPTIONSSCHEIN LONG - ASTRAZENECA | Market Closed - Börse Stuttgart 05:28:59 2024-05-31 am EDT | ||
| 0.32 EUR | +18.52% |
|
| Current month | -20.00% | ||
| 1 month | -20.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.32 | +18.52% |
| 24-05-30 | 0.27 | +107.69% |
| 24-05-29 | 0.13 | -71.11% |
| 24-05-28 | 0.45 | -28.57% |
| 24-05-27 | 0.63 | -1.56% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 05:28 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GG73PT |
| ISIN | DE000GG73PT4 |
| Date issued | 2024-04-26 |
| Strike | 11,842 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.74 € |
|---|---|
| Lowest since issue | 0.13 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
